ArticleJournal of biological methods2025
Exhale-Dx™: A non-invasive, real-time breath analysis system using deep learning for asthma diagnosis.
Article in Journal of biological methods, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Asthma presents significant diagnostic and therapeutic challenges, impacting millions and posing a substantial burden on healthcare systems, particularly in the United Kingdom, where it afflicts roughly 5.4 million individuals. Severe asthma, incurring over 50% of total expenditures, tends to lead to frequent exacerbations and preventable emergency admissions. Traditional diagnostic methods, primarily based on clinical history, can result in delays and misdiagnoses, culpable for over 1,200 deaths annually, 90% of which are considered preventable with timely intervention. Objective: To address this issue, we developed Exhale-Dx™, a point-of-care breath test platform that provides a non-invasive, user-friendly solution for asthma diagnosis and monitoring. Exhale-Dx™ captures volatile organic compounds (VOCs) in exhaled breath, reflecting real-time metabolic and inflammatory markers of lung function. By analyzing these personalized breath signatures, clinicians and patients can detect exacerbations up to three days in advance, thus facilitating early and targeted interventions to reduce emergency care utilization. The system integrates capnographic waveforms, asthma control scores, and clinical lung function data, offering a comprehensive diagnostic profile. Methods: Using Exhale-Dx™ data, we developed the Asthma Diagnostic Enhanced Neural Architecture (ADENA), an advanced deep neural network that leverages VOC biomarkers and lung function data to enhance diagnostic precision. Results: ADENA achieved exceptional performance, delivering 98.7% accuracy, an F1 score of 0.98, and a low mean squared error of 0.065. The deconvolution analysis further confirmed the model's ability to detect significant physiological differences between asthmatic and non-asthmatic profiles. Conclusion: Our findings showed that VOC analysis combined with advanced neural networks could accurately distinguish asthmatic profiles, highlighting their potential for early, non-invasive interventions in respiratory health diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.